# Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Canonical URL: https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-participate-at-the-h-c-wainwright-28th-annual-global-inve-b1f74bbb
Ticker: ELTX
Company: Elicio Therapeutics, Inc.
Source: Elicio Therapeutics, Inc.
Published: 2026-08-31 12:00 EST
## Summary

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company...

## Article Body
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.

H.C. Wainwright 28th Annual Global Investment Conference Format : Fireside Chat Date : Monday, September 14, 2026 Time : 2:00 PM ET

The live webcast and replay of the presentation will be available here and on Elicio’s Events page for 90 days following the event.

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your H.C. Wainwright representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com .

Investor Relations Contact Brian Ritchie LifeSci Advisors (212) 915-2578 britchie@lifesciadvisors.com
## Recent Company News
- 2026-08-31 12:00 EST — [Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-participate-at-the-h-c-wainwright-28th-annual-global-inve-b1f74bbb) — Source: Elicio Therapeutics, Inc.
- 2026-08-24 12:00 EST — [Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-to-participate-at-the-wells-fargo-21st-annual-healthcare-con-70d9d6c7) — Source: Elicio Therapeutics, Inc.
- 2026-08-13 20:01 EST — [Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-122253de) — Source: Elicio Therapeutics, Inc.
- 2026-08-10 12:00 EST — [Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-activation-of-the-investigator-initiated-phase-1-s-671df539) — Source: Elicio Therapeutics, Inc.
- 2026-07-06 20:05 EST — [Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering-a94b4898) — Source: Elicio Therapeutics, Inc.
## Related News
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)